These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19631789)

  • 1. The risk of unintended pregnancies in users of the contraceptive patch compared to users of oral contraceptives in the UK General Practice Research Database.
    Jick SS; Hagberg KW; Kaye JA; Jick H
    Contraception; 2009 Aug; 80(2):142-51. PubMed ID: 19631789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal contraceptive patch system Evra: a comparison between adolescent and adult users.
    Bodner K; Bodner-Adler B; Grünberger W
    Arch Gynecol Obstet; 2011 Mar; 283(3):525-30. PubMed ID: 20111970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
    Jick SS; Hagberg KW; Hernandez RK; Kaye JA
    Contraception; 2010 Jan; 81(1):16-21. PubMed ID: 20004268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives.
    Rosenberg MJ; Waugh MS; Long S
    J Reprod Med; 1995 May; 40(5):355-60. PubMed ID: 7608875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA; Norman H; Doherty M; Walker AM
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Brenner P
    Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
    [No Abstract]   [Full Text] [Related]  

  • 11. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.
    Zieman M; Guillebaud J; Weisberg E; Shangold GA; Fisher AC; Creasy GW
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S13-8. PubMed ID: 11849631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.
    Archer DF; Bigrigg A; Smallwood GH; Shangold GA; Creasy GW; Fisher AC
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S27-31. PubMed ID: 11849633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early home abortion and immediate contraception with Evra® patch].
    Mention JE; Lanta S; Dréan Y; Lalou Y; Barbier M
    J Gynecol Obstet Biol Reprod (Paris); 2011 Sep; 40(5):415-8. PubMed ID: 21377812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra).
    Zieman M
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629
    [No Abstract]   [Full Text] [Related]  

  • 17. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction.
    Jick SS; Jick H
    Pharmacotherapy; 2007 Feb; 27(2):218-20. PubMed ID: 17253912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evra--a patch on oral contraception?
    Drug Ther Bull; 2003 Dec; 41(12):89-91. PubMed ID: 14723093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative trials of low-dose combined oral contraceptives.
    Edelman DA; Kothenbeutel R; Levinski MJ; Kelly SE
    J Reprod Med; 1983 Mar; 28(3):195-200. PubMed ID: 6854550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 150/30 formulation. Experience in the United Kingdom.
    Guillebaud J
    J Reprod Med; 1983 Jan; 28(1 Suppl):66-70. PubMed ID: 6403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.